Search for: "Astrazeneca" Results 521 - 540 of 1,244
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Feb 2013, 6:16 pm by Aaron Barkoff
RELATED READING: GSK Request for Advisory Opinion dated Jan. 10, 2005 AstraZeneca Request for Advisory Opinion dated Aug. 10, 2006 AstraZeneca Request for Advisory Opinion dated June 21, 2007 Forest Labs Request for Advisory Opinion dated May 12, 2011 [read post]
28 Jan 2013, 7:16 am by Dennis Crouch
AstraZeneca is seeking a Senior or Principal Patent Attorney for managing its broad IP portfolio. [read post]
13 Jan 2013, 11:07 am
According to experts, AstraZeneca has known about the risk of Nexium bone side effects since 2006. [read post]
9 Jan 2013, 9:59 pm by Patent Docs
By Andrew Williams -- Late last year, in AstraZeneca v. [read post]
20 Dec 2012, 12:20 pm by Rantanen
  The short version is that Astrazeneca has won for the time being: the Federal Circuit ruled in favor of Astrazeneca on all issues. [read post]
22 Nov 2012, 9:01 am
The Court of Appeal in Shared Network Services has now granted leave to appeal against another decision of Flaux J, in which he presumably follows his reasoning in Astrazeneca. [read post]
20 Nov 2012, 7:50 am
* On Thursday 6 December, judgment will be given in Case C‑457/10 P AstraZeneca AB and Astra Zeneca plc v European Commission. [read post]
12 Nov 2012, 10:40 am by Michelle Yeary
AstraZeneca Pharmaceutical, Inc., 203 Fed. [read post]
29 Oct 2012, 1:57 pm
The disconcerting thing about these lawsuits is that Nexium’s manufacturer, AstraZeneca has produced documents in litigation that seem to indicate that they knew about the risks of broken bones, but didn’t warn their customers until the FDA made the move. [read post]
29 Oct 2012, 1:57 pm
The disconcerting thing about these lawsuits is that Nexium’s manufacturer, AstraZeneca, has produced documents in litigation that seem to indicate that they knew about the risks of broken bones, but didn’t warn their customers until the FDA made the move. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
7 Sep 2012, 5:29 am
The drugs in question are Boehringer Iingelheim’s Pradaxa, AstraZeneca’s Caprelsa, and Novartis’ Gilenya. [read post]
5 Sep 2012, 9:45 am by JA Hodnicki
ABSTRACT: If the Court of Justice follows the Advocate General's advice and upholds the General Court's judgment in AstraZeneca, this... [read post]
5 Sep 2012, 9:45 am by JA Hodnicki
ABSTRACT: If the Court of Justice follows the Advocate General's advice and upholds the General Court's judgment in AstraZeneca, this... [read post]
3 Sep 2012, 9:21 am by Cal Warriner
A company memo also said AstraZeneca had buried unfavorable studies. [read post]
3 Sep 2012, 5:41 am by Ray Mullman
In 2010, AstraZeneca had $5.3 billion in worldwide sales including $3.75 billion in the U.S. [read post]